WCLC 2025 | Challenges and opportunities in thymic carcinoma research
Martina Imbimbo, MD, Ente Ospedaliero Cantonale, Lugano, Switzerland, highlights the hurdles in researching rare tumors like thymic carcinoma, citing limited funding and population size as major obstacles. However, recent studies assessing ramucirumab plus carboplatin and paclitaxel offer promising avenues for treatment. To further advance research and standard of care, international networks and initiatives are needed to facilitate collaborative trials and real-world data collection. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is another tough area because it’s a rare tumor so it’s very hard to have research in rare tumors so I think that the big advantage is the last year was the publication of the study that we designed in Milan with Ramucirumab with Cabazitaxel for thymic carcinoma and first line they were presented at ESMO last year and then there are trials and another trial now with the IO and chemotherapy in first line for thymic carcinoma...
So this is another tough area because it’s a rare tumor so it’s very hard to have research in rare tumors so I think that the big advantage is the last year was the publication of the study that we designed in Milan with Ramucirumab with Cabazitaxel for thymic carcinoma and first line they were presented at ESMO last year and then there are trials and another trial now with the IO and chemotherapy in first line for thymic carcinoma. But it’s true that it’s very hard to have research, funding is missing, population is rare, so it’s also very important that we team up on a national international levels to have these networks. This is what we are presenting at this conference today, so the institution of the Swiss network for thymic malignancies, because this can help not only standard of care but also research and we could do like collaborative trials and this is very important also you know from real-world data to confirm what we see in very small phase two trials so it’s very important to have these kind of initiatives you
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
